Advertisement: TTP Killer 50
7 March, 2022 - 11:20 By Tony Quested

Adrestia Therapeutics

Adrestia Therapeutics secured undisclosed Series A  investment from GSK in 2020 to progress technology designed to restore diseased cells by deploying a different gene in the cell to counter harmful genetic defects.

Founded by prolific ‘dontrepreneur’ Professor Steve Jackson in 2018, the company is pioneering synthetic viability. Professor Jackson and his lab were the brains behind KuDOS Pharma, bought by AstraZeneca, and the new blockbuster drug Lynparza which AZ is commercialising globally.

Adrestia’s technology is designed to restore diseased cells by deploying a different gene in the cell to counter harmful genetic defects. In 2021 the company set up its headquarters on the Babraham Research Campus and embarked on a significant recruitment drive.

Job opportunities at Adrestia Therapeutics

 

Newsletter Subscription

Stay informed of the latest news and features